It seems like investors are especially obsessed with the psychology of decision making -- high stakes, after all -- but all kinds of decisions, whether in life or business -- like dating, product management, what to eat or watch on Netflix -- are an "investment portfolio" of decisions... even if you sometimes feel like you're making one big decision at a time (like, say, marriage or what product to develop next or who to hire). Obviously, not all decisions are equal; in fact, sometimes we don't even have to spend any time deciding. So how do we know which decisions to apply a robust decision process too, which ones not to? What are the strategies, mindsets, tools to help us decide? How can we operationalize a good decision process and decision hygiene into our teams and organizations? After all, we're tribal creatures -- our opinions are infectious (for better and for worse) -- so how do we convey vs. convince, and not necessarily agree but inform to decide? Especially given common pitfalls (resulting, hindsight bias, etc.), and "the paradox of experience", including even (and more so) winning vs. losing. Decision expert (and leading poker player) Annie Duke comes back on the a16z Podcast -- after our first conversation with her for Thinking in Bets, which focused mainly on WHY our decision making gets so frustrated -- to talk about her new book, which picks up where the last left off, on HOW to Decide: Simple Tools for Better Choices. In conversation with a16z managing partner Jeff Jordan (and former CEO of OpenTable and former GM of eBay among other things) -- so, from all sides of investing, operating, life -- Annie shares tips for decision makers of all kinds making decisions under uncertainty... really, all of us.   The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, this content may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein. This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets) is available at https://a16z.com/investments/. Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.

Welcome to the second episode of Bio Eats World, a brand new podcast all about how biology is technology. Bio is breaking out of the lab and clinic and into our daily lives -- on the verge of revolutionizing our world in ways we are only just beginning to imagine. Many diseases are caused by proteins that have gone haywire in some fashion. There could be too much of the protein, it could be mutated, or it could be present in the wrong place or time. So how do you get rid of these problematic proteins? In this episode of Journal Club (now on Bio Eats World), Stanford professor Carolyn Bertozzi and host Lauren Richardson discuss the article “Lysosome-targeting chimaeras for degradation of extracellular proteins” by Steven Banik, Kayvon Pedram, Simon Wisnovsky, Green Ahn, Nicholas Riley, and Carolyn Bertozzi, published in Nature (2020). Dr. Bertozzi and  her lab developed a class of drugs — or modality — that tosses the disease-related proteins into the cellular trash can. While there are other drugs that work through targeted protein degradation, these drugs called LYTACs are able to attack a set of critical proteins, some of which have never been touched by any kind of drug before. The conversation covers how they engineered these new drugs, their benefits, and how they can be further optimized and specialized in the future.